Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models

TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells

“…Huh7, Huh6, and HepG2 cells were cultured in Dulbecco's modified Eagle medium (Thermo Fisher Scientific, Waltham, MA, USA) and the other cell lines were grown in RPMI-1640 medium (Thermo Fisher Scientific). The cells were maintained in medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C in a humidified 5% CO 2 incubator, and were regularly assessed to confirm the absence of mycoplasma contamination, as previously described 37 . Recombinant human TGF-β1 (R&D Systems, Minneapolis, MN, USA) was added to the cultures 18 h after pre-incubation in medium containing 2% FBS; the TGF-β1 and media were replaced every 3 days to prevent depletion if needed.…”

“…Whole-cell lysates were prepared with lysis buffer, as previously described 37 . Cell fractions of the plasma membrane and cytosol were isolated with the Mem-PER™ Plus Membrane Protein Extraction Kit (Thermo Fisher Scientific) according to the manufacturer's instructions and protein concentrations were determined using the Bradford protein assay (Bio-Rad, Hercules, CA, USA).…”

Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells

“…NSCLC cells with a KRAS mutation were highly sensitive to treatment with TRAIL and 5-fluorouracil (5FU) [64] . Sequential administration of 5-FU plus selumetinib would be a promising strategy for patients having KRAS or BRAF mutant colon cancers [65] . Oncogenic KRAS sensitized colorectal tumor cells to oxaliplatin and 5-FU in a p53-dependent manner [66] .…”

A graphene gold nanocomposite-based 5-FU drug and the enhancement of the MCF-7 cell line treatment

“…1 Statistical studies indicated that the majority of cases were about 9.7 million in 2002 and are expected to reach 16 million by 2025, especially in developing countries. [2][3][4][5][6][7][8][9] Many parameters may increase the efficacy of 5-uorouracil (5-FU) against the development of the disease as breast cancer includes genetic, environmental, natural and physiological factors; [10][11][12][13][14] chemotherapy, hormone therapy and targeted therapy summarize the main approaches that are approved for curing breast cancer, but each method has its own side effects and drawbacks. Chemotherapy has very dangerous side effects; on the other hand, hormone and targeted therapy are selective to various types of cancers.…”